A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

June 19, 2023

Study Completion Date

June 19, 2023

Conditions
COVID-19
Interventions
DRUG

HH-120 nasal spray

Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.

DRUG

HH-120 nasal spray

Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.

DRUG

Placebo Comparator

Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.

DRUG

Placebo Comparator

Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.

Trial Locations (16)

100000

Qujing First People's Hospital, Qujing

100015

Beijing Ditan Hospital, Capital Medical University, Beijing

100050

Beijing Friendship Hospital,Capital Medical University, Beijing

100191

Peking University Third Hospital, Beijing

124000

Panjin Liaoyou Gem flower Hospital, Panjin

130021

The First Hospital of Jilin University, Changchun

214200

Yixing People's Hospital, Wuxi

222042

Lianyungang Oriental Hospital, Lianyungang

325000

Wenzhou Traditional Chinese Medicine Hospital, Wenzhou

350025

Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou

411100

Xiangtan Central Hospital, Xiangtan

510515

Nanfang Hospital,Southern Medical University, Guangzhou

525200

The People's Hospital of Gaozhou, Gaozhou

610017

Chengdu Second People's Hospital, Chengdu

661199

Southern Central Hospital Of Yunnan Province(The First People's Hospital Of Honghe State), Yisa

041000

Linfen Central Hospital, Linfen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Huahui Health

INDUSTRY

NCT05713318 - A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19 | Biotech Hunter | Biotech Hunter